pain opportunity underappreciated. Acute pain trial result to be disclosed soon. The biotech developing a drug to treat acute pain that is not an opioid., a stock in the CNBC Investing Club portfolio, gets price target cut to $82 per share from $102 at Wells Fargo. Keeps equal weight rating.
price target to $55 per share from $60. The analysts' earnings estimates ahead of quarter are largely in-line with consensus.Jim's Charitable Trust31-year-old teacher quit her job. Now she works at Costco—and boosted her income by 50%: ‘I've never been happier'I left the U.S. for Denmark. Now I pay $2,100/month to live in this luxury apartment—and I'm much happier here
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: